Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $23.26, but opened at $22.50. Chugai Pharmaceutical shares last traded at $23.15, with a volume of 340,633 shares.
Chugai Pharmaceutical Stock Performance
The stock has a 50 day moving average of $25.45 and a 200-day moving average of $24.40. The firm has a market capitalization of $76.45 billion, a P/E ratio of 28.68 and a beta of 0.66.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.19 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.71% and a net margin of 33.56%. The firm had revenue of $1.89 billion for the quarter. As a group, sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
See Also
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access